Pharmaceutical News and Articles

Coverage for Routine Childhood Vaccines Remains Below Prepandemic Levels

Three years after the start of the COVID-19 pandemic, coverage for selected routine childhood vaccines remained below prepandemic levels, according to a study p

Powerful MRI Scans Aid Epilepsy Surgery

The first sign of seizures for Amanda Bradbury were auras in her vision that cropped up around age 19. Then came frequent bouts of anxiety, struggling to mainta

Black Americans Twice As Likely To Die During Childhood As Whites

Black babies and children are more than twice as likely to die as white kids, and that gap has grown since the 1950s, a new study says. Black kids died at a rat

New Material Allows Amputees To Adjust Prosthetic Limb Fit Via Smartphone

Chafing, blisters and sores are common problems for people fitted with an artificial limb. The artificial limb s fixed, rigid shape can t adapt to changes in a

New Moms Benefit From Regular Workouts

Childbirth is an overwhelming accomplishment, but new mothers would do best not to rest on their laurels following delivery, a new guideline says. New moms shou

Tobacco Control Has Saved Nearly 4 Millions Lives, Study Estimates

Tobacco control measures like anti-smoking campaigns and cigarette taxes have prevented nearly 4 million lung cancer deaths during the past five decades, a new

Palatin’s Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency

CRANBURY, N.J., March 25, 2025 PRNewswire Palatin Technologies, Inc. (NYSE American PTN), a biopharmaceutical company developing first-in-class medicines based

Tolebrutinib Regulatory Submission Accepted for Priority Review in the US for Patients with Multiple Sclerosis

The United Laboratories and Novo Nordisk Announce Exclusive License Agreement for UBT251, a GLP-1/GIP/Glucagon Triple Receptor Agonist

Guangdong, China and Bagsv rd, Denmark, 24 March 2025 The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A S (Novo Nordisk) today ann

FDA Approves Blujepa for Uncomplicated Urinary Tract Infections

The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women (wei